Actavia Life Sciences, Inc.

Equities

RASP

US7538881068

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:28:19 2024-04-26 pm EDT			5-day change	1st Jan Change
0.0173 ^USD	+121.79%		+121.79%	+124.68%

Feb. 16	Actavia Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI
Jan. 05	Actavia Life Sciences, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	CI

Actavia Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023

February 16, 2024 at 03:47 pm EST

Actavia Life Sciences, Inc. reported earnings results for the first quarter ended December 31, 2023. For the first quarter, the company reported net loss was USD 0.147637 million compared to USD 0.149844 million a year ago.

Latest news about Actavia Life Sciences, Inc.

Actavia Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 16	CI
Actavia Life Sciences, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 05	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-14	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-15	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-03-02	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	23-02-09	CI
Rasna Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	23-02-08	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-08-22	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	22-06-21	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	22-06-16	CI
Rasna Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	22-06-09	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021	22-03-01	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021	21-08-16	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021	21-06-02	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2020	21-04-05	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2020	21-01-15	CI
Rasna Therapeutics, Inc. Announces Board Changes	20-12-28	CI
Rasna Therapeutics, Inc Announces Board Changes	20-10-15	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2020	20-08-19	CI
Rasna Therapeutics, Inc. Announces Executive Changes	20-08-18	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2020	20-06-30	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2019	20-02-14	CI
Kunwar Shailubhai Resigns as Chief Executive Officer of Rasna Therapeutics, Inc	20-02-06	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2019	20-01-13	CI
Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2019	19-08-02	CI

Chart Actavia Life Sciences, Inc.

Duration

Period

More charts

Company Profile

Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACTAVIA LIFE SCIENCES, INC.	+124.68%	13.35M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs